Previous 10 | Next 10 |
PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team wi...
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...
- BBP-671 detected in healthy volunteer plasma and cerebrospinal fluid (CSF), suggesting that BBP-671 is entering the brain, a location critical to target neurological complications of PKAN and organic acidemias at their source - Results showed BBP-671 increased whole blood acet...
BridgeBio Pharma (NASDAQ:BBIO) and its affiliate company Phoenix Tissue Repair said that their protein replacement therapy PTR-01 was safe and led to durable healing in patients with recessive dystrophic epidermolysis bullosa (RDEB) in a phase 2 trial. The company is presenting data...
- PTR-01 was well-tolerated over a four-month treatment period in RDEB patients - Treatment with PTR-01 led to rapid, consistent, and durable wound healing as observed in reduction of wound surface area and clinician-reported assessments - All patients that complet...
Gainers: Palo Alto Networks (PANW) +11%. Bioceres Crop Solutions (BIOX) +7%. VectivBio Holding AG (VECT) +7%. Aveanna Healthcare Holdings (AVAH) +6%. Fate Therapeutics (FATE) +5%. Losers: Foghorn Therapeutics (FHTX) -26%. Ross Stores (ROST) -23%. Atara Biotherapeutics (A...
PALO ALTO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team wil...
The commercial-stage biotech BridgeBio Pharma (NASDAQ:BBIO) has signed an agreement with an undisclosed acquirer to sell the rare pediatric disease Priority Review Voucher (PRV) it received last year for $110 million, the company said Friday. The completion of the deal is subject to certain c...
- Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110 million - Secured a two-year extension of interest-only period on its existing senior secured credit facility PALO ALTO, Cal...
- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties -SHP2 inhibitor deal expands earlier agreement between BridgeBio and Bristol Myers Squibb to study BBP-398 in...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...